PEPPERELL

Cancer Incidence by Sex, 1993 - 1997

Expected and Observed Case Counts, with Standardized Incidence Ratios

| | Exp | <u>Obs</u> | SIR | | Exp | <u>Obs</u> | SIR |
|-----------------------|---------------|-------------|------------------|-------------------------|-------|------------|-----|
| Bladder, Urina | ary | | Melanoma of Skin | | | | |
| Male | 4.24 | 8 | 189 | Male | 3.13 | 4 | NC* |
| Female | 1.61 | 4 | NC* | Female | 2.55 | 1 | NC* |
| Total | 5.85 | 12 | 205 #+ | Total | 5.68 | 5 | 88 |
| Brain and Oth | er Central No | ervous Syst | <u>tem</u> | Multiple Myeloma | | | |
| Male | 1.88 | 3 | NC* | Male | 0.83 | 1 | NC* |
| Female | 1.52 | 2 | NC* | Female | 0.77 | 1 | NC* |
| Total | 3.40 | 5 | 147 | Total | 1.61 | 2 | NC* |
| Breast | | | | Non-Hodgkin's Lymphoma | | | |
| Male | 0.29 | 1 | NC* | Male | 4.11 | 1 | NC* |
| Female | 30.74 | 35 | 114 | Female | 3.25 | 4 | NC* |
| Total | 31.04 | 36 | 116 | Total | 7.35 | 5 | 68 |
| Cervix Uteri | | | | Oral Cavity and Pharynx | | | |
| | | | | Male | 3.47 | 3 | NC* |
| Female | 2.26 | 7 | 309 #+ | Female | 1.52 | 2 | NC* |
| | | | | Total | 4.99 | 5 | 100 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 10.85 | 11 | 101 | | | | |
| Female | 10.29 | 5 | 49 | Female | 3.81 | 3 | NC* |
| Total | 21.15 | 16 | 76 | | | | |
| Esophagus | | | | Pancreas | | | |
| Male | 1.73 | 1 | NC* | Male | 1.75 | 1 | NC* |
| Female | 0.52 | 1 | NC* | Female | 1.71 | 0 | NC* |
| Total | 2.25 | 2 | NC* | Total | 3.46 | 1 | NC* |
| Hodgkin's Disc | ease | | Prostate | | | | |
| Male | 1.04 | 0 | NC* | Male | 26.79 | 25 | 93 |
| Female | 0.77 | 3 | NC* | | | | |
| Total | 1.82 | 3 | NC* | | | | |
| Kidney and Re | enal Pelvis | | Stomach | | | | |
| Male | 2.93 | 5 | 171 | Male | 1.92 | 1 | NC* |
| Female | 1.65 | 1 | NC* | Female | 1.12 | 0 | NC* |
| Total | 4.58 | 6 | 131 | Total | 3.04 | 1 | NC* |
| <u>Larynx</u> | | | | Testis | | | |
| Male | 1.78 | 2 | NC* | Male | 1.56 | 2 | NC* |

| Female | 0.49 | 1 | NC* | | | | | |
|--|-------|----|-----|----------------|--------------------------------------|-----|-----|--|
| Total | 2.27 | 3 | NC* | | | | | |
| Leukemia | | | | Thyroid | | | | |
| Male | 2.25 | 1 | NC* | Male | 0.75 | 0 | NC* | |
| Female | 1.69 | 2 | NC* | Female | 1.90 | 5 | 263 | |
| Total | 3.94 | 3 | NC* | Total | 2.64 | 5 | 189 | |
| Liver and Intrahepatic Bile Ducts | | | | Uteri, Corp | Uteri, Corpus and Uterus, NOS | | | |
| Male | 0.98 | 1 | NC* | | | | | |
| Female | 0.37 | 0 | NC* | Female | 5.78 | 2 | NC* | |
| Total | 1.34 | 1 | NC* | | | | | |
| Lung and Bronchus | | | | All Sites / T | All Sites / Types | | | |
| Male | 14.68 | 10 | 68 | Male | 93.81 | 90 | 96 | |
| Female | 11.05 | 13 | 118 | Female | 91.87 | 96 | 104 | |
| Total | 25.73 | 23 | 89 | Total | 185.68 | 186 | 100 | |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels